CAMBRIDGE, United Kingdom and NEW YORK, December 19, 2024 β 91Ώμ²₯ Limited (βArtiosβ), a clinical-stage biotech company led by pioneers of DNA damage response (β91Ώμ²₯β) drug development, today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco from January 13 to 16, 2025.
Niall Martin, PhD, Artiosβ Chief Executive Officer, will present the company’s strategic vision for 2025 and beyond on January 16 at 08:00 am PST (11:00 am EST / 04:00 pm UTC) in the Elizabethan C room at The Westin St. Francis, 335 Powell Street, San Francisco.
About 91Ώμ²₯ Ltd.
Artios leads the DNA damage response field through its comprehensive anti-cancer approach and the deep experience of its team of pioneering 91Ώμ²₯ drug developers. The companyβs clinical-stage candidates, ATR inhibitor ART0380 and Polymerase theta (PolΞΈ) inhibitor ART6043 are designed with differentiated pharmaceutical properties and novel biological approaches to precisely eliminate a cancer cellβs remaining survival mechanisms. Artiosβ mission is to develop new classes of 91Ώμ²₯ drugs that achieve an unreached level of therapeutic impact for patients with hard-to-treat solid tumors.
Visit our website at to learn more about the company.
For more information, please contact:
91Ώμ²₯ Ltd.
Niall Martin, CEO
Email: info@artios.com
Media Inquiries
Trophic Communications
Jacob Verghese or Verena Schossmann
Tel: +49 151 7441 6179
Email: artios@trophic.eu